

Supplemental Table 5: Adverse events

Adverse Effect Category	Abatacept		Placebo	
	No. of Events	No. of Subjects (%)	No. of Events	No. of Subjects (%)
Infections and infestations	82	38 (37.6)	89	45 (40.5)
Gastrointestinal disorders	34	22 (21.8)	29	21 (18.9)
Musculoskeletal and connective tissue	25	19 (18.8)	26	15 (13.5)
Respiratory, thoracic and mediastinal disorders	25	16 (15.8)	22	15 (13.5)
General disorders and administration site	17	14 (13.9)	24	20 (18.0)
Skin and subcutaneous tissue disorders*	22	17 (16.8)	15	10 (9.0)
Nervous system disorders	19	13 (12.9)	13	8 (7.2)
Injury, poisoning and procedural	19	15 (14.9)	12	8 (7.2)
Psychiatric disorders	8	7 (6.9)	13	9 (8.1)
Surgical and medical procedures	9	9 (8.9)	9	9 (8.1)
Investigations	5	3 (3.0)	12	10 (9.0)
Metabolism and nutrition disorders	6	5 (5.0)	6	4 (3.6)
Eye disorders	6	5 (5.0)	5	4 (3.6)
Reproductive system and breast disorders	7	3 (3.0)	3	3 (2.7)
Blood and lymphatic system disorders	3	3 (3.0)	7	7 (6.3)
Cardiac disorders	5	3 (3.0)	3	3 (2.7)
Vascular disorders	2	2 (2.0)	4	4 (3.6)
Endocrine disorders	4	3 (3.0)	2	2 (1.8)
Pregnancy, puerperium and perinatal	5	2 (2.0)	0	0 (0.0)
Neoplasms benign, malignant and unspecified (including cysts and polyps cysts and polyps)	4	4 (4.0)	2	2 (1.8)
Immune system disorders	2	2 (2.0)	3	3 (2.7)
Renal and urinary disorders	3	3 (3.0)	1	1 (0.9)
Ear and labyrinth disorders	2	2 (2.0)	2	2 (1.8)
Hepatobiliary disorders	2	2 (2.0)	0	0 (0.0)
Total Events	314	---	301	---